These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 1362802)

  • 1. Monoclonal antibodies to glomerular antigens.
    Ronco P; Sahali D; Cittanova ML; van Leer EH; Chatelet F; Verroust P
    Nephrol Dial Transplant; 1992; 7 Suppl 1():9-15. PubMed ID: 1362802
    [No Abstract]   [Full Text] [Related]  

  • 2. Heymann nephritis: a model of human membranous glomerulopathy. A study of the role of additional antigens.
    van Leer EH; Ronco P; Verroust P; de Roo GM; Hoedemaeker PJ; de Heer E
    Nephrol Dial Transplant; 1992; 7 Suppl 1():1-8. PubMed ID: 1362800
    [No Abstract]   [Full Text] [Related]  

  • 3. Antigenic targets in epimembranous glomerulonephritis. Experimental data and potential application in human pathology.
    Ronco P; Allegri L; Brianti E; Chatelet F; Van Leer EH; Verroust P
    Appl Pathol; 1989; 7(2):85-98. PubMed ID: 2567175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic effects of anti-gp330 and anti-dipeptidyl peptidase type IV antibodies in the induction of glomerular damage.
    van Leer EH; de Roo GM; Bruijn JA; Hoedemaeker PJ; de Heer E
    Exp Nephrol; 1993; 1(5):292-300. PubMed ID: 7915960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Involvement of an antigen distinct from the Heymann antigen in membranous glomerulonephritis in the mouse.
    Assmann KJ; Ronco P; Tangelder MM; Lange WP; Verroust P; Koene RA
    Lab Invest; 1989 Jan; 60(1):138-46. PubMed ID: 2642986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular aspects of immune deposit formation in Heymann nephritis.
    Kerjaschki D
    Nephrol Dial Transplant; 1992; 7 Suppl 1():16-20. PubMed ID: 1283449
    [No Abstract]   [Full Text] [Related]  

  • 7. [Immunopathogenesis of glomerulonephritis--new data on the clinical and experimental studies].
    Krzymański M
    Przegl Lek; 1992; 49(1-2):10-2. PubMed ID: 1454997
    [No Abstract]   [Full Text] [Related]  

  • 8. Identification of gp108, a pathogenic antigen of passive Heymann nephritis, as dipeptidyl peptidase IV.
    Natori Y; Hayakawa I; Shibata S
    Clin Exp Immunol; 1987 Nov; 70(2):434-9. PubMed ID: 2892601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-induced redistribution of Heymann antigen on the surface of cultured glomerular visceral epithelial cells: possible role in the pathogenesis of Heymann glomerulonephritis.
    Camussi G; Brentjens JR; Noble B; Kerjaschki D; Malavasi F; Roholt OA; Farquhar MG; Andres G
    J Immunol; 1985 Oct; 135(4):2409-16. PubMed ID: 3875653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membranous nephropathy. Insights from Heymann nephritis.
    Cavallo T
    Am J Pathol; 1994 Apr; 144(4):651-8. PubMed ID: 8160766
    [No Abstract]   [Full Text] [Related]  

  • 11. Differential capacity of anti-RAP and anti-megalin antibodies to produce progressive passive Heymann nephritis - implications for the pathogenesis of idiopathic human membranous glomerulonephritis.
    Makker SP; Tramontano A
    J Pathol; 2006 Nov; 210(3):282-7. PubMed ID: 16981232
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isologous monoclonal antibodies can induce anti-GBM glomerulonephritis in rats.
    Sado Y; Kagawa M; Rauf S; Naito I; Moritoh C; Okigaki T
    J Pathol; 1992 Oct; 168(2):221-7. PubMed ID: 1460540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Megalin/GP330 and pathogenetic concepts of membranous glomerulopathy (MGN).
    Kerjaschki D
    Kidney Blood Press Res; 2000; 23(3-5):163-6. PubMed ID: 11031710
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibodies to glycolipids activate complement and promote proteinuria in passive Heymann nephritis.
    Susani M; Schulze M; Exner M; Kerjaschki D
    Am J Pathol; 1994 Apr; 144(4):807-19. PubMed ID: 8160779
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The immune complex pathogenesis of experimental membranous glomerulopathy (Heymann nephritis) and its significance in human glomerular disease].
    Kerjaschki D
    Verh Dtsch Ges Pathol; 1989; 73():24-35. PubMed ID: 2482609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal complement synthesis in glomerulonephritis.
    Ravnskov V
    Lancet; 1994 Jan; 343(8891):235-6. PubMed ID: 7904688
    [No Abstract]   [Full Text] [Related]  

  • 17. Heymann nephritis revisited--new insights into the pathogenesis of experimental membranous glomerulonephritis.
    De Heer E; Bruijn JA; Hoedemaeker PJ
    Clin Exp Immunol; 1993 Dec; 94(3):393-4. PubMed ID: 8252799
    [No Abstract]   [Full Text] [Related]  

  • 18. Studies with monoclonal antibodies against brush border antigens in Heymann nephritis.
    Bhan AK; Schneeberger EE; Baird LG; Collins AB; Kamata K; Bradford D; Erikson ME; McCluskey RT
    Lab Invest; 1985 Oct; 53(4):421-32. PubMed ID: 3900581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isolation and characterization of circulating immune complexes from rats with experimental membranous nephropathy.
    Hori MT; Abrass CK
    J Immunol; 1990 May; 144(10):3849-55. PubMed ID: 2185315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The duality of Heymann nephritis antigen and immunogenoside--a minute quantity of a membranous nephritis-causing substance contained in somewhat crude nephritogenoside].
    Shibata S
    Arerugi; 1988 Jul; 37(7):397-403. PubMed ID: 3063233
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.